EC Follow-Up & Survival Analysis 3

Question 1

In electrolysis survival analysis, the term 'survival rate' of a follicle refers to what?

Accepted Answer

The percentage of treated follicles that successfully regrow hair

Answer

In this context, follicle 'survival' means it retains the ability to regrow hair, so a high follicle survival rate indicates treatment was less effective.

Question 2

Which hair cycle phase is associated with the highest risk of follicle survival (regrowth) after electrolysis?

Accepted Answer

Telogen

Answer

Follicles in telogen have a retracted dermal papilla that may not receive a lethal energy dose, making them more likely to survive treatment and regrow.

Question 3

A client has completed 20 sessions over 18 months. How should an electrologist objectively evaluate the overall treatment outcome?

Accepted Answer

Compare hair density photographs from the start of treatment with current density

Answer

Standardized photographs taken at baseline and at intervals provide objective, comparable data on hair density reduction over the treatment series.

Question 4

What is the primary reason why a complete analysis of treatment permanency cannot be made until at least 12 months after the final session?

Accepted Answer

All hair follicles must have had the opportunity to cycle through anagen at least once

Answer

Hair follicles on different cycle timelines may not enter anagen—and thus show regrowth—until a year has passed, making any earlier permanency claim premature.

Question 5

A client on hormone replacement therapy (HRT) shows higher-than-expected regrowth rates at follow-up. What is the most likely explanation?

Accepted Answer

HRT can stimulate vellus follicles to transition to terminal hairs, creating new growth

Answer

HRT, especially androgen therapy, can activate previously dormant vellus follicles, producing apparent 'regrowth' that is actually new terminal hair growth.

(EC) Electrolysis Certification Practice Test

(EC) Electrolysis Certification Practice Test

EC Follow-Up & Survival Analysis 3